


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sbpgroup.com](http://www.sbpgroup.com)*

**(Stock code: 1177)**

**APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS AND  
CHANGE OF COMPOSITION OF BOARD COMMITTEES**

This announcement is made by Sino Biopharmaceutical Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

**APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS**

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that Dr. Chen Lieping and Dr. Lu Bai have been appointed as independent non-executive Directors with effect from the conclusion of the annual general meeting of the Company convened and held on 17 June 2026.

**Dr. Chen Lieping**

The biographical details of Dr. Chen are set out below:

Dr. Chen Lieping (陳列平), aged 69, is a globally recognised pioneer in cancer immunotherapy with over 40 years of experience in fundamental research and drug development in the fields of immunology and oncology. He is a member of both the National Academy of Sciences and the National Academy of Medicine of the United States. Dr. Chen currently serves as the United Technologies Corporation Professor in Cancer Research and Professor of Immunology, Dermatology and Medical Oncology at Yale School of Medicine. Dr. Chen obtained his Bachelor of Medicine degree from Fujian Medical University in 1982, a Master of Science degree from Peking Union Medical College in 1986, and a Ph.D. from Drexel University College of Medicine in 1989.

Dr. Chen's career spans both academia and industry. He served as a research scientist at Bristol-Myers Squibb from 1990 to 1997. He subsequently held faculty positions at the Mayo Clinic and the Johns Hopkins University School of Medicine for a number of years before joining Yale University in 2010. Dr. Chen was the first to discover the PD-L1 (B7-H1) molecule and to elucidate its critical role in tumour immune evasion. He subsequently initiated and organised the world's first clinical trial of an antibody drug blocking the PD-1/PD-L1 pathway and pioneered the use of PD-L1 expression as a predictive biomarker for therapeutic efficacy, thereby laying a solid scientific and clinical foundation for the successful development of therapies in this field. In addition, his laboratory has discovered and characterised over 20 novel immunomodulatory molecules, advancing drug development programmes targeting multiple frontier targets. Currently, 4-1BB agonists and antibodies against B7-H4, Siglec-15 and CD93 have entered Phase II clinical trials, while B7-H3 has become a prominent developmental target encompassing antibody-drug conjugates (ADCs), bispecific antibodies and CAR-T therapies.

Dr. Chen previously served as an independent non-executive director of Shanghai Junshi Biosciences Co., Ltd. (上海君實生物醫藥科技股份有限公司) (SSE: 688180; HKEX: 1877) and has acted as a scientific advisor to pharmaceutical companies including Pfizer Inc. (NYSE: PFE), AstraZeneca PLC (LSE, NYSE and STO: AZN), Boehringer Ingelheim and Johnson & Johnson (NYSE: JNJ). He currently serves as a scientific advisor to Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), NextCure, Inc. (NASDAQ: NXTC), Tioneer Biotech, DynamiCure Biotechnology, Normunity, Inc. and OncoC4, Inc.

Under the letter of appointment entered into between Dr. Chen and the Company, his term of service is two years. His directorship with the Company shall be subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company. Dr. Chen's remuneration is HK\$2,400,000 per annum, which is determined by the Board and the remuneration committee of the Company with reference to his experience, duties and responsibilities within the Company.

## **Dr. Lu Bai**

The biographical details of Dr. Lu are set out below:

Dr. Lu Bai (魯白), aged 69, has long been committed to the research of neurotrophic factors and synaptic plasticity, as well as neurodegenerative and psychiatric diseases, and is a world-renowned neurobiologist.

Dr. Lu is currently the Director of Shanghai Academy of Natural Sciences (上海市尚思自然科學研究院) and a Professor at Fudan University (復旦大學) in Shanghai. Dr. Lu is the founder of 4B Technologies (Beijing) Co., Limited (福貝生物醫藥科技(北京)有限公司), a biotech company specialising in the development of transformative medicines for nervous system diseases, and the co-founder of BioFront Therapeutics (Beijing) Co., Ltd. (百放英庫醫藥科技(北京)有限公司), a company aiming to identify disease drivers and develop first-in-class therapeutics through profit-sharing partnerships with academic investigators. Dr. Lu also serves as a scientific adviser and a director of Gnosis Healthineer (Beijing) Co., Ltd (靈犀醫學科技(北京)有限公司) since February 2022, providing scientific advice. He currently serves as the Chair of the Scientific Advisory Board of Shanghai Pharmaceuticals Holding Co., Ltd.,

Shanghai Hospital Development Center and ACTIS (Academy for Clinical Innovation and Translation of Shanghai). He is a Director of Chinese Institutes for Medical Research and Chief Scientist of the Advanced Innovation Center for Human Brain Protection.

Dr. Lu was a Professor at the School of Pharmaceutical Sciences of Tsinghua University (清華大學) from January 2016 to May 2024, and served as the Professor of the Department of Pharmacology and Pharmaceutical Science and the Executive Vice Dean of the Medical School of Tsinghua University from October 2013 to January 2016. From December 2009 to September 2013, Dr. Lu was a guest professor at Tsinghua University. From July 2009 to October 2013, Dr. Lu served as the Vice President of the R&D centre of GlaxoSmithKline China. Dr. Lu joined the National Institutes of Health (NIH) in 1996 and served as the Chief of the Neural Development and Plasticity Section of NIH and the Associate Director of the Division of Cognitive and Mental Health of a trans-NIH translational research program (GCAP) from January 1996 to June 2009. Dr. Lu served as a researcher in Roche Institute of Molecular Biology and an associate professor in the Department of Biological Sciences of Columbia University from June 1993 to December 1995.

Dr. Lu received a bachelor's degree in biology from East China Normal University (華東師範大學) in the PRC in June 1982, a doctoral degree in neurobiology from Cornell University in the United States in June 1990 and then worked in postdoctoral research at Rockefeller University in the United States from July 1990 to June 1993.

Dr. Lu has been serving as an independent non-executive director of Jacobio Pharmaceuticals Group Co., Ltd (加科思藥業集團有限公司) (stock code: 1167) since 23 March 2023, the shares of which are listed on the Main Board of the Stock Exchange.

Under the letter of appointment entered into between Dr. Lu and the Company, his term of service is two years. His directorship with the Company shall be subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company. Dr. Lu's remuneration is HK\$415,800 per annum, which is determined by the Board and the remuneration committee of the Company with reference to his experience, duties and responsibilities within the Company.

Save as disclosed above, as at the date of this announcement, each of Dr. Chen and Dr. Lu does not (i) hold any other position in the Company and other members of the Group; (ii) hold any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) hold any other major appointments and professional qualifications.

As at the date of this announcement, each of Dr. Chen and Dr. Lu has no relationships with any Director, senior management, substantial or controlling shareholders (having the meaning ascribed to it in the Listing Rules) of the Company and does not have any interests in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Each of Dr. Chen and Dr. Lu confirmed (i) his independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Group or any connection with any core connected persons (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed above, there are no other matters relating to the appointments of Dr. Chen and Dr. Lu that need to be brought to the attention of the shareholders of the Company, and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

## **CHANGE OF COMPOSITION OF BOARD COMMITTEES**

The Board further announces that immediately following the appointments of Dr. Chen and Dr. Lu, (i) Dr. Chen has been appointed as a member of each of the audit committee, remuneration committee and nomination committee of the Company; and (ii) Dr. Lu has been appointed as a member of the audit committee of the Company.

The Board would like to express a warm welcome to Dr. Chen and Dr. Lu for joining the Company.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 17 June 2026

*As at the date of this announcement, the Board of the Company comprises five executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.*